Global Antibody Drug Conjugates Market Analysis 2018
Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells. The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Request a Sample Copy of This Report: https://www.radiantinsights.com/research/global-antibody-drug-conjugates-drug-sales/request-sample Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs ...